World

Russia registers third Covid-19 vaccine

Jab developed using inactive virus, first 120,000 doses to be distributed among civilians in mid-March

Updated 5 years ago · Published on 20 Feb 2021 5:30PM

Russia registers third Covid-19 vaccine
Russia’s CoviVac is due to complete final-stage clinical trials in March and has so far been recommended for people under 60. – AFP pic, February 20, 2021

MOSCOW – Moscow announced today it has registered its third vaccine against the coronavirus and promised to introduce the jab to the Russian population by March.

Russia was the first country to register a vaccine against Covid-19 in August ahead of clinical trials, and the Sputnik V jab has been authorised in more than two dozen countries.

“Today we note that a third vaccine, CoviVac, has been registered,” Prime Minister Mikhail Mishustin said at a government meeting broadcast on state television.

“And already in mid-March, the first 120,000 doses will be distributed within the civilian circulation,” he told the cabinet.

First greeted with scepticism, the effectiveness of Sputnik V was confirmed by the Lancet medical journal earlier this month.

Moscow relied on the nationwide roll-out of the vaccine to stave off the impact of a second wave of infections that battered the country late last year.

But mortality data released recently revealed that Russia’s death rate is still one of the highest in the world.

President Vladimir Putin announced in October that the country had registered its second vaccine, EpiVacCorona, which health officials had said would enter mass production this month.

Mishustin said today that Russia has produced 10 million doses of Sputnik and 80,000 batches of the EpiVacCorona vaccine developed by the Siberian Vektor laboratory.

With the introduction of the third jab Saturday, the prime minister said: “Today, Russia is the only country in which there are already three vaccines for the prevention of Covid-19 infection.”

CoviVac was produced by the state-run Chumakov Centre based in Moscow, which employed a different method of development from Sputnik V and EpiVacCorona, using an inactive virus.

The vaccine is due to complete its final-stage clinical trial with 3,000 participants in March and has so far been recommended for people below the age of 60. – AFP, February 20, 2021

Related News

Malaysia / 1w

Dr Noor Hisham denies claims that the Pfizer vaccine caused deaths

Education / 1mth

Zambry leads Malaysia delegation to Russia for bilateral cooperation talks

Opinion / 2mth

Wikipedia has become compromised by intelligence agencies and ideological capture

World / 2mth

Why Russia is expanding the Northern Sea Route

Education / 3mth

Malaysia must embrace AI in education to avoid falling behind

LENS: KL / 5mth

Russian Embassy in Kuala Lumpur holds special May Day remembrance

Spotlight

Malaysia

Five fatal helicopter crash victims honoured in Sarawak state awards

Malaysia

No Malaysian is left behind; Budget 2027 puts people first - Anwar  

Malaysia

Panama hit by 6.4-magnitude earthquake

Malaysia

Haze blankets 33 areas with unhealthy air

Malaysia

Malaysia’s 2027 Budget is a steady one: people-oriented continuity rather than bold reform

Malaysia

Budget 2027: What is in it for me?

Malaysia

Budget 2027 steps up Sabah, Sarawak funding by RM2.2b amid push for development parity

Malaysia

Budget 2027: Maternity leave entitlement increased, minimum pension raised to RM1,350

You may be interested

World

Anak Krakatau raised to second-highest alert after 13 eruptions

World

Trump lifts sanctions on Russian diesel as US fuel prices soar ahead of midterms

World

Trump calls for Zelenskiy’s removal after deadly Russian strike kills 20 in Ukraine

World

Trump weighs joining Saudi strikes after deadly Houthi attack on Riyadh airport

World

Trump attacks Norway after Nobel Peace Prize goes to Navi Pillay

World

Bangladesh to deploy army at two new posts near Rohingya camps amid rising crime

World

Gaza ceasefire leaves 2.1 million Palestinians squeezed into 35% of territory as attacks continue